Loading...

AgeX Therapeutics

AMEX:AGE
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AGE
AMEX
$115M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of cellular and regenerative therapeutics for diseases of old age in the United States. The last earnings update was 7 days ago. More info.


Add to Portfolio Compare Print
  • AgeX Therapeutics has significant price volatility in the past 3 months.
AGE Share Price and Events
7 Day Returns
-32.9%
AMEX:AGE
2.3%
US Biotechs
1.6%
US Market
1 Year Returns
-
AMEX:AGE
-4%
US Biotechs
2.6%
US Market
AGE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
AgeX Therapeutics (AGE) -32.9% -31.1% -28.7% - - -
US Biotechs 2.3% -0.6% -5.4% -4% 7.5% 12.9%
US Market 1.6% -1.7% 2.1% 2.6% 38.5% 41.4%
1 Year Return vs Industry and Market
  • No trading data on AGE.
  • No trading data on AGE.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

AGE Value

 Is AgeX Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for AgeX Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $3.06.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for AgeX Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are AgeX Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AMEX:AGE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.29
AMEX:AGE Share Price ** AMEX (2019-05-21) in USD $3.06
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,087 Publicly-Listed Companies 17.74x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of AgeX Therapeutics.

AMEX:AGE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:AGE Share Price ÷ EPS (both in USD)

= 3.06 ÷ -0.29

-10.45x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AgeX Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • AgeX Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does AgeX Therapeutics's expected growth come at a high price?
Raw Data
AMEX:AGE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.45x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.23x
United States of America Market PEG Ratio Median Figure of 2,123 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for AgeX Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on AgeX Therapeutics's assets?
Raw Data
AMEX:AGE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.25
AMEX:AGE Share Price * AMEX (2019-05-21) in USD $3.06
United States of America Biotechs Industry PB Ratio Median Figure of 415 Publicly-Listed Biotechs Companies 3.32x
United States of America Market PB Ratio Median Figure of 5,202 Publicly-Listed Companies 1.84x
AMEX:AGE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:AGE Share Price ÷ Book Value per Share (both in USD)

= 3.06 ÷ 0.25

12.35x

* Primary Listing of AgeX Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AgeX Therapeutics is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess AgeX Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. AgeX Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AGE Future Performance

 How is AgeX Therapeutics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AgeX Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.6%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is AgeX Therapeutics expected to grow at an attractive rate?
  • Unable to compare AgeX Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare AgeX Therapeutics's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare AgeX Therapeutics's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
AMEX:AGE Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.8%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AMEX:AGE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AMEX:AGE Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 2 -9 -10
2018-12-31 1 -8 -8
2018-09-30 2 -8 -6
2018-06-30 2 -7 -6
2018-03-31 1 -7 -4
2017-12-31 1 -6 -7
2016-12-31 2 -8 -15

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if AgeX Therapeutics is high growth as no earnings estimate data is available.
  • Unable to determine if AgeX Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AMEX:AGE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from AgeX Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AMEX:AGE Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.29
2018-12-31 -0.21
2018-09-30 -0.17
2018-06-30 -0.17
2018-03-31 -0.14
2017-12-31 -0.21
2016-12-31 -0.54

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if AgeX Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine AgeX Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. AgeX Therapeutics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. AgeX Therapeutics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess AgeX Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
AgeX Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AGE Past Performance

  How has AgeX Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare AgeX Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • AgeX Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare AgeX Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare AgeX Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
AgeX Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from AgeX Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AMEX:AGE Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 1.55 -10.40 6.47 5.58
2018-12-31 1.40 -7.50 5.65 5.83
2018-09-30 1.54 -5.82 4.37 5.57
2018-06-30 1.54 -5.63 3.84 5.77
2018-03-31 1.38 -4.31 3.78 5.68
2017-12-31 1.40 -6.58 3.87 5.78
2016-12-31 1.67 -15.49 5.62 8.48

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if AgeX Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if AgeX Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if AgeX Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess AgeX Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
AgeX Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AGE Health

 How is AgeX Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up AgeX Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • AgeX Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • AgeX Therapeutics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of AgeX Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • AgeX Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from AgeX Therapeutics Company Filings, last reported 1 month ago.

AMEX:AGE Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 10.03 0.00 8.59
2018-12-31 8.23 0.00 6.71
2018-09-30 10.74 0.00 8.76
2018-06-30 12.21 0.00 11.36
2018-03-31 8.97 0.00 8.52
2017-12-31 8.32 0.00 7.38
2016-12-31 -22.38 0.00 0.26
  • AgeX Therapeutics has no debt.
  • AgeX Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • AgeX Therapeutics has less than a year of cash runway based on current free cash flow.
  • AgeX Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 12% each year.
X
Financial health checks
We assess AgeX Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. AgeX Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AGE Dividends

 What is AgeX Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from AgeX Therapeutics dividends.
If you bought $2,000 of AgeX Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate AgeX Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate AgeX Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AMEX:AGE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2003 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as AgeX Therapeutics has not reported any payouts.
  • Unable to verify if AgeX Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of AgeX Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as AgeX Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess AgeX Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can AgeX Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. AgeX Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AGE Management

 What is the CEO of AgeX Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike West
COMPENSATION $1,137,846
AGE 65
CEO Bio

Dr. Michael D. West, also known as Mike, Ph.D., serves as President and Chief Executive Officer of AgeX Therapeutics, Inc. He has been Chairman of the Board of LifeMap Sciences, Inc. since 2019. Dr. West serves as a Scientific Advisor of OncoCyte Corporation. Dr. West served as the Co-Chief Executive Officer of BioTime, Inc. from October 10, 2007 to September 17, 2018 and also served as its President until December 5, 2017. Dr. West serves as the Chief Executive Officer of Embryome Sciences, Inc. He served as Vice President of Technology Integration at Asterias Biotherapeutics, Inc. and previously served in the same position from March 2013 to December 22, 2015. Prior to BioTime, he served as Chief Executive Officer, President and Chief Scientific Officer of Advanced Cell Technology, Inc. from 1998 to 2007. He served as the Chief Executive Officer and President of Asterias Biotherapeutics, Inc. from April 10, 2014 to June 9, 2014. He served as the Chief Scientific Officer of LifeMap Sciences, Inc. He served as the Chief Executive Officer of ES Cell International Pte Ltd. He served as a Consultant of Ocata Therapeutics, Inc. from December 2007 to December, 31 2007. He served as the Chairman of Ocata Therapeutics, Inc. until November 2006 and served as its President and Chief Scientific Officer until October 2007. He served as the Chairman, President and Chief Scientific Officer of A.C.T. Holdings Inc. since January 24, 2005. He served as the Chairman, President and Chief Scientific Officer at Two Moons Kachinas, Inc. He is widely regarded as one of the leaders and founders of the field of regenerative medicine and stem cell research. He has an extensive academic and business experience in age-related degenerative diseases, telomerase molecular biology and human embryonic stem cell research and development, where he initiated and managed programs in telomerase diagnostics, telomerase inhibition, telomerase-mediated therapy and human embryonic stem cell research. He founded Geron Corporation in 1990 and served as its Vice President of New Technologies from 1990 to 1998. He organized and managed the collaboration that led to the discovery of human embryonic stem and human embryonic germ cells. He served as Chairman of the Board at Saratoga Hospital, Inc. and serves as its Trustee. He co-founded and served as the Chairman of Origen Therapeutics. He serves as a Director of ES Cell International Pte Ltd., LifeMap Sciences, Inc. and Cell Cure Neurosciences Ltd. He serves as a Director of AgeX Therapeutics, Inc since January 2017. He serves as a Member of the Scientific Advisory Board at BioMarker Pharmaceuticals, Inc. He served as a Director of BioMarker Pharmaceuticals, Inc. He served as a Director of Ocata Therapeutics, Inc. until December 31, 2007, Geron Corporation from 1990 to 1998, OncoCyte Corporation from September 2009 to August 15, 2016 and A.C.T. Holdings Inc. since January 2005. He serves as a Director of the Life Extension Foundation. He served as a Director of BioTime, Inc. from October 2002 and Asterias Biotherapeutics, Inc. from September 2012 to September 17, 2018. Dr. West received a B.S. Degree from Rensselaer Polytechnic Institute in 1976, an M.S. Degree in Biology from Andrews University in 1982 and a Ph.D. from Baylor College of Medicine concentrating on the Biology of Cellular aging in 1989.

CEO Compensation
  • Insufficient data for Mike to compare compensation growth.
  • Mike's remuneration is higher than average for companies of similar size in United States of America.
Management Team

Mike West

TITLE
President
COMPENSATION
$1M
AGE
65

Hal Sternberg

TITLE
Vice President of Research
COMPENSATION
$184K
AGE
65
TENURE
1.8 yrs

Russell Skibsted

TITLE
Chief Financial Officer
AGE
59
TENURE
2.3 yrs

Nafees Malik

TITLE
Chief Operating Officer
Board of Directors Tenure

Average tenure and age of the AgeX Therapeutics board of directors in years:

1
Average Tenure
62
Average Age
  • The average tenure for the AgeX Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Greg Bailey

TITLE
Chairman of the Board
AGE
62
TENURE
0.1 yrs

Mike West

TITLE
President
COMPENSATION
$1M
AGE
65
TENURE
2.3 yrs

Michael Mulroy

TITLE
Director
COMPENSATION
$45K
AGE
52
TENURE
2.3 yrs

John Mauldin

TITLE
Director
AGE
68
TENURE
1 yrs

Annalisa Jenkins

TITLE
Director
AGE
53
TENURE
0.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
13. Dec 18 Buy Michael West Individual 10. Dec 18 10. Dec 18 4,000 $3.86 $15,443
X
Management checks
We assess AgeX Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. AgeX Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AGE News

Simply Wall St News

AGE Company Info

Description

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of cellular and regenerative therapeutics for diseases of old age in the United States. The company’s lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. was founded in 2017 and is based in Alameda, California.

Details
Name: AgeX Therapeutics, Inc.
AGE
Exchange: AMEX
Founded: 2017
$115,147,800
37,630,000
Website: http://www.agexinc.com
Address: AgeX Therapeutics, Inc.
1010 Atlantic Avenue,
Suite 102,
Alameda,
California, 94501,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX AGE Common Shares NYSE MKT LLC US USD 29. Nov 2018
DB 0X4 Common Shares Deutsche Boerse AG DE EUR 29. Nov 2018
Number of employees
Current staff
Staff numbers
12
AgeX Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/22 07:17
End of day share price update: 2019/05/21 00:00
Last earnings filing: 2019/05/15
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.